Ruthenium(II)–Arene RAPTA Type Complexes Containing Curcumin and Bisdemethoxycurcumin Display Potent and Selective Anticancer Activity

A series of novel ruthenium(II) arene RAPTA type derivatives (arene = cymene, hexamethylbenzene) containing curcumin-based ligands (curcH = curcumin, bdcurcH = bisdemethoxycurcumin) and PTA (1,3,5-triaza-7-phosphaadamantane) have been synthesized and fully characterized. The solid-state structures of [Ru(cym)(curc)(PTA)][SO3CF3], [Ru(hmb)(curc)(PTA)][SO3CF3], and [Ru(hmb)(bdcurc)(PTA)][SO3CF3] have been determined by single-crystal X-ray diffraction. The antitumor activity of the complexes has been evaluated in vitro against human ovarian carcinoma cells (A2780 and A2780cisR), as well as against nontumorous human embryonic kidney (HEK293) cells. The correlation of the cytotoxicity upon switching the curcumin-based ligands, i.e. curcumin vs bisdemethoxycurcumin, is not straightforward. In contrast, the PTA ligand greatly enhances the activity and selectivity of ruthenium compounds in comparison to previously reported compounds.

[1]  U. Rothlisberger,et al.  Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity , 2014, Nature Communications.

[2]  Nicole S. Bryce,et al.  Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study , 2013 .

[3]  Nicolas P E Barry,et al.  Exploration of the medical periodic table: towards new targets. , 2013, Chemical communications.

[4]  L. Juillerat-Jeanneret,et al.  Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death. , 2013, Dalton transactions.

[5]  W. Berger,et al.  Metal–Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation , 2013, Organometallics.

[6]  V. Moreno,et al.  Preparation of new half sandwich ruthenium arene complexes with aminophosphines as potential chemotherapeutics. , 2012, Journal of inorganic biochemistry.

[7]  M. Mozzicafreddo,et al.  Arene–RuII Complexes of Curcumin Exert Antitumor Activity via Proteasome Inhibition and Apoptosis Induction , 2012, ChemMedChem.

[8]  P. Dyson,et al.  Naphthalimide-tagged ruthenium-arene anticancer complexes: combining coordination with intercalation , 2012 .

[9]  P. Dyson,et al.  Challenges and Opportunities in the Development of Organometallic Anticancer Drugs , 2012 .

[10]  D. Miklavčič,et al.  Synthesis and Biological Evaluation of the Thionated Antibacterial Agent Nalidixic Acid and Its Organoruthenium(II) Complex , 2012 .

[11]  P. Kondaiah,et al.  Remarkable photocytotoxicity of curcumin in HeLa cells in visible light and arresting its degradation on oxovanadium(IV) complex formation. , 2012, Chemical communications.

[12]  P. Sadler,et al.  Designing organometallic compounds for catalysis and therapy. , 2012, Chemical communications.

[13]  E. Monti,et al.  Ruthenium-arene complexes of curcumin: X-ray and density functional theory structure, synthesis, and spectroscopic characterization, in vitro antitumor activity, and DNA docking studies of (p-cymene)Ru(curcuminato)chloro. , 2012, Journal of medicinal chemistry.

[14]  Carol Imbriano,et al.  Newly synthesized curcumin derivatives: crosstalk between chemico-physical properties and biological activity. , 2011, Journal of medicinal chemistry.

[15]  Gregory S. Smith,et al.  Targeted and multifunctional arene ruthenium chemotherapeutics. , 2011, Dalton transactions.

[16]  A. Casini,et al.  Organometallic ruthenium(II) arene compounds with antiangiogenic activity. , 2011, Journal of medicinal chemistry.

[17]  M. Jakupec,et al.  Physicochemical Studies and Anticancer Potency of Ruthenium η6-p-Cymene Complexes Containing Antibacterial Quinolones , 2011, Organometallics.

[18]  A. Casini,et al.  Organometallic ruthenium-based antitumor compounds with novel modes of action , 2011 .

[19]  D. Benaki,et al.  Curcumin as the OO bidentate ligand in "2 + 1" complexes with the [M(CO)3]+ (M = Re, 99mTc) tricarbonyl core for radiodiagnostic applications. , 2011, Inorganic chemistry.

[20]  M. Jakupec,et al.  Ruthenium− and Osmium−Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity , 2010, Organometallics.

[21]  G. Gasser,et al.  Organometallic Anticancer Compounds , 2010, Journal of medicinal chemistry.

[22]  Shonagh Walker,et al.  The status of platinum anticancer drugs in the clinic and in clinical trials. , 2010, Dalton transactions.

[23]  G. Süss-Fink.  Arene ruthenium complexes as anticancer agents. , 2010, Dalton transactions.

[24]  D. K. Agrawal,et al.  Curcumin and its analogues: Potential anticancer agents , 2009, Medicinal research reviews.

[25]  L. Juillerat-Jeanneret,et al.  Rational design of an organometallic glutathione transferase inhibitor. , 2009, Angewandte Chemie.

[26]  M. Saladini,et al.  Synthesis, cytotoxic and combined cDDP activity of new stable curcumin derivatives. , 2009, Bioorganic & medicinal chemistry.

[27]  L. Ding,et al.  Syntheses, characterization and biological activities of rare earth metal complexes with curcumin and 1,10-phenanthroline-5,6-dione. , 2009, Journal of inorganic biochemistry.

[28]  Christian G Hartinger,et al.  Bioorganometallic chemistry--from teaching paradigms to medicinal applications. , 2009, Chemical Society reviews.

[29]  A. Valentini,et al.  Synthesis, oxidant properties, and antitumoral effects of a heteroleptic palladium(II) complex of curcumin on human prostate cancer cells. , 2009, Journal of medicinal chemistry.

[30]  Anna F. A. Peacock,et al.  Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. , 2008, Chemistry, an Asian journal.

[31]  L. Martins,et al.  Cu(I) complexes bearing the new sterically demanding and coordination flexible tris(3-phenyl-1-pyrazolyl)methanesulfonate ligand and the water-soluble phosphine 1,3,5-triaza-7-phosphaadamantane or related ligands. , 2008, Inorganic chemistry.

[32]  W. Berger,et al.  KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients , 2008, Chemistry & biodiversity.

[33]  P. Dyson,et al.  The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways , 2008, JBIC Journal of Biological Inorganic Chemistry.

[34]  Carsten A. Vock,et al.  Influence of the Diketonato Ligand on the Cytotoxicities of [Ru(η6-p-cymene)(R2acac)(PTA)]+ Complexes (PTA = 1,3,5-triaza-7-phosphaadamantane) , 2008 .

[35]  M. Jakupec,et al.  Antitumour metal compounds: more than theme and variations. , 2008, Dalton transactions.

[36]  L. Juillerat-Jeanneret,et al.  Organometallic Ruthenium Inhibitors of Glutathione‐S‐Transferase P1‐1 as Anticancer Drugs , 2007, ChemMedChem.

[37]  B. Aggarwal,et al.  Role of curcumin in cancer therapy. , 2007, Current problems in cancer.

[38]  P. Sadler,et al.  Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity. , 2006, Inorganic chemistry.

[39]  Irfan Rahman,et al.  Regulation of inflammation and redox signaling by dietary polyphenols. , 2006, Biochemical pharmacology.

[40]  R. Scopelliti,et al.  Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. , 2006, Inorganic chemistry.

[41]  M. Jakupec,et al.  From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). , 2006, Journal of inorganic biochemistry.

[42]  J. McNeill,et al.  Synthesis and characterization of dual function vanadyl, gallium and indium curcumin complexes for medicinal applications. , 2005, Journal of inorganic biochemistry.

[43]  P. Dyson,et al.  In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. , 2005, Journal of medicinal chemistry.

[44]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[45]  J. Schellens,et al.  A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.

[46]  G. Pezzoni,et al.  Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  Loes M. J. Kroon-Batenburg,et al.  An intensity evaluation method: EVAL-14 , 2003 .

[48]  A. Bergamo,et al.  Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine. , 1999, Anticancer research.

[49]  J. B. Lambert,et al.  Organic Structural Spectroscopy , 1998 .

[50]  W. Fuss,et al.  Chlor(trifluorphosphan)gold(I), eine einfache flüchtige Notizen: Goldverbindung/Chloro(trifluorophosphane)gold(I), a Simple Volatile Gold Compound , 1992 .

[51]  T. Kruck,et al.  Mitteilungen über Metalltrifluorphosphan‐Komplexe, 51. Hexakis(trifluorphosphan)vanadium(0)‐Synthese, Eigenschaften und Reaktionen , 1990 .

[52]  S. O. Nielsen,et al.  ACIDITY MEASUREMENTS WITH THE GLASS ELECTRODE IN H2O-D2O MIXTURES , 1960 .

[53]  J. Schellens,et al.  Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. , 2012, Journal of inorganic biochemistry.

[54]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[55]  B. Aggarwal,et al.  Anticancer potential of curcumin: preclinical and clinical studies. , 2003, Anticancer research.

[56]  C. S. Allardyce,et al.  [Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells , 2001 .

[57]  R. Blessing,et al.  An empirical correction for absorption anisotropy. , 1995, Acta crystallographica. Section A, Foundations of crystallography.

[58]  T. Kruck.  Trifluorophosphine Complexes of Transition Metals , 1967 .